Lupartumab provides an investigational monoclonal antibody platform for oncology and antibody research and specifically supports studies of antibody-mediated tumor targeting, antigen recognition, and cancer cell interactions. Researchers can use it to specifically investigate antibody binding and cellular responses in models expressing its intended target antigen.
Key Features and Benefits
- LYPD3-Targeting Antibody: Recognizes LYPD3, also known as C4.4A, a cell-surface protein associated with epithelial tumor biology.
- Human Monoclonal Antibody: Provides a human IgG1 antibody platform specifically for investigating selective antigen recognition.
- C4.4A Recognition: Supports investigation of LYPD3 expression, antibody binding, and tumor-associated antigen targeting.
- Tumor Cell Targeting: Enables studies of antibody interactions with LYPD3-expressing cancer cells.
- ADC Development Platform: Provides the antibody component associated with Lupartumab Amadotin (BAY 1129980), an investigational ADC.
- Cellular Internalization Research: Supports investigation of antibody uptake and intracellular trafficking in relevant cancer models.
- Antibody Engineering Research: Especially useful for studying monoclonal antibody design, antigen specificity, and conjugation strategies.
Applications
- Non-Small Cell Lung Cancer Research: Supports investigation of LYPD3-targeted antibody strategies in relevant NSCLC models.
- Squamous Cell Carcinoma Research: Especially useful for studying C4.4A expression and antibody recognition in squamous cell carcinoma models.
- LYPD3-Positive Cancer Research: Supports investigation of antigen expression and antibody binding in LYPD3-expressing tumors.
- Tumor Antigen Research: Useful for examining the role of C4.4A in tumor-associated cellular processes.
- ADC Research: Provides a targeting antibody platform specifically for investigating LYPD3-directed payload conjugation and delivery.
- Antibody Binding Assays: Supports evaluation of antigen recognition, binding specificity, and antibody-cell interactions.
- Cellular Internalization Studies: Useful for investigating receptor-associated antibody uptake and intracellular trafficking.
- Comparative Antibody Research: Supports comparison of LYPD3-targeting antibodies and tumor antigen recognition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Lupartumab targets the LYPD3/C4.4A tumor-associated antigen and provides a platform for antibody-mediated cancer cell recognition and specifically supports lung cancer, squamous cell carcinoma, tumor antigen, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
